MPR Weekly Dose 112 - Second COVID-19 Booster Dose Authorized; Sotrovimab Use Limited; Oral COVID-19 Tx; PreHevbrio Hep B Vaccination; Thyroid Dysfunction Alert Following ICM

<p><span style="font-weight: 400;">A second booster dose for some COVID-19 vaccines is authorized; Sotrovimab has its use limited due to the BA.2 Omicron subvariant; An investigational oral antiviral gains Fast Track designation; PreHevbrio hepatitis B vaccine now available; And the FDA update a safety communication regard the risk of thyroid dysfunction in infants following the use of contrast media containing iodine.</span></p>